The American Journal of Managed Care

Identifying Appropriate Candidates for NGS Testing

Kanwal Raghav, MD, MBBS, discusses appropriate candidates for HER2 testing and current utilization strategies for biomarker testing in mCRC. We’re routinely using next-generation sequencing [NGS] in ...
Labroots

Break the ceiling: Elevate your oncology NGS testing with expert-curated data

When the Precision Medicine Initiative was launched in 2015, it completely transformed patient care in oncology. Now, individual differences in genetics, environment and lifestyle, along with the ...
GEN

Reimbursing NGS Testing

New Working Group to Evaluate Clinical Utility of NGS-Based Testing to Inform Coverage After many years of steady development in DNA sequencing, the scientific community is reaching an exciting ...
The American Journal of Managed Care

Challenges to NGS Testing for Follicular Lymphoma in the Community Setting

While next-generation sequencing (NGS) has become routine in academic settings, its use for patients with follicular lymphoma in the community is less consistent. There are disparities in the ...
Healthcare Dive

CMS widens NGS test coverage for inherited breast, ovarian cancers

A single NGS test can analyze DNA for millions of genomic variations that can reveal a person's risk for developing certain genetic diseases, which could potentially help guide treatment. NGS-based ...
Labroots

test NGS testing and the single day sequencing workflow

Targeted NGS has been instrumental in helping the healthcare community deliver on the promise of precision medicine. The Ion Torrent Genexus Integrated Sequencer has enabled targeted genomic ...

Meridian Life Science Expands Ambient-Stable NGS Portfolio with the Launch of a Lyophilized Enzymatic DNA Fragmentation Kit

The Life Science division of Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, today announced the launch of its Lyophilized NGS ...
Healio

Most patients with advanced cancer do not undergo next-generation sequencing testing

Please provide your email address to receive an email when new articles are posted on . Real-world data show that only about 30% to 40% of patients with the most common cancers receive NGS testing.
ascopubs.org

Economic Impact of Next-Generation Sequencing Versus Single-Gene Testing to Detect Genomic Alterations in Metastatic Non–Small-Cell Lung Cancer Using a Decision Analytic Model

In a hypothetical 1,000,000-member health plan, 2,066 Medicare-insured patients and 156 commercially insured patients were estimated to have mNSCLC and to be eligible for testing. Time-to-test results ...
Medscape

First Guideline on NGS Testing in Cancer, From ESMO

Recommendations on the use of next-generation sequencing (NGS) tests for patients with metastatic cancer have been issued by the European Society for Medical Oncology (ESMO), the first recommendations ...
ascopubs.org

NGS for cancer testing: A clinical laboratory’s perspective.

Clinical utility of next-generation sequencing (NGS)-based genomic profiling of advanced solid tumors in routine clinical practice. This is an ASCO Meeting Abstract from the 2018 ASCO Annual Meeting I ...